Frontiers in EndocrinologyPub Date : 2025-03-18eCollection Date: 2025-01-01DOI: 10.3389/fendo.2025.1485311
Zheng Bi, Jinju Li, Qiongyi Liu, Zhaohui Fang
{"title":"Deep learning-based optical coherence tomography and retinal images for detection of diabetic retinopathy: a systematic and meta analysis.","authors":"Zheng Bi, Jinju Li, Qiongyi Liu, Zhaohui Fang","doi":"10.3389/fendo.2025.1485311","DOIUrl":"10.3389/fendo.2025.1485311","url":null,"abstract":"<p><strong>Objective: </strong>To systematically review and meta-analyze the effectiveness of deep learning algorithms applied to optical coherence tomography (OCT) and retinal images for the detection of diabetic retinopathy (DR).</p><p><strong>Methods: </strong>We conducted a comprehensive literature search in multiple databases including PubMed, Cochrane library, Web of Science, Embase and IEEE Xplore up to July 2024. Studies that utilized deep learning techniques for the detection of DR using OCT and retinal images were included. Data extraction and quality assessment were performed independently by two reviewers. Meta-analysis was conducted to determine pooled sensitivity, specificity, and diagnostic odds ratios.</p><p><strong>Results: </strong>A total of 47 studies were included in the systematic review, 10 were meta-analyzed, encompassing a total of 188268 retinal images and OCT scans. The meta-analysis revealed a pooled sensitivity of 1.88 (95% CI: 1.45-2.44) and a pooled specificity of 1.33 (95% CI: 0.97-1.84) for the detection of DR using deep learning models. All of the outcome of deep learning-based optical coherence tomography ORs ≥0.785, indicating that all included studies with artificial intelligence assistance produced good boosting results.</p><p><strong>Conclusion: </strong>Deep learning-based approaches show high accuracy in detecting diabetic retinopathy from OCT and retinal images, supporting their potential as reliable tools in clinical settings. Future research should focus on standardizing datasets, improving model interpretability, and validating performance across diverse populations.</p><p><strong>Systematic review registration: </strong>https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42024575847.</p>","PeriodicalId":12447,"journal":{"name":"Frontiers in Endocrinology","volume":"16 ","pages":"1485311"},"PeriodicalIF":3.9,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11958191/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Association and mediation between circulating inflammatory proteins and skin fibrosis.","authors":"Zirui Zhao, Dongming Lv, Ruixi Zeng, Yanchao Rong, Zhongye Xu, Rong Yin, Zhicheng Hu, Xiaoling Cao, Bing Tang","doi":"10.3389/fendo.2025.1416993","DOIUrl":"10.3389/fendo.2025.1416993","url":null,"abstract":"<p><strong>Objective: </strong>Skin fibrosis is a dermal lesion associated with inflammatory factors. However, the exact causal relationship between circulating inflammatory proteins (CIPs) and skin fibrosis remains unclear. To investigate this potential association and mediated effect, Mendelian randomization (MR) and two-step MR were used.</p><p><strong>Methods: </strong>Summary statistics from genome-wide association studies (GWAS) were extracted from the GWAS Catalog for CIPs, blood metabolites (BMs), and skin fibrosis. Two-sample MR and reverse MR were conducted to determine the effect of CIPs on skin fibrosis. Two-step MR was then performed to investigate the role of BMs in mediating the effect of CIPs on skin fibrosis. Reverse MR analysis was performed to confirm the unidirectional causality between CIPs and BMs, as well as between BMs and skin fibrosis.</p><p><strong>Results: </strong>Bidirectional Mendelian randomization revealed negative associations between skin fibrosis and the levels of T-cell surface glycoprotein CD6 isoform (odds ratio [OR] 0.670 [95% confidence interval [CI] 0.472, 0.951], <i>p</i> = 0.025), Delta and Notch-like epidermal growth factor-related receptor (OR 0.779 [95% CI 0.609, 0.998], <i>p</i> = 0.048), and Interleukin-10 receptor subunit beta (OR 0.541 [95% CI 0.332, 0.884], <i>p</i> = 0.014). There was a positive association between skin fibrosis and levels of Fibroblast growth factor 21 (OR 2.276 [95% CI 1.064, 4.870], <i>p</i> = 0.034). Two-step MR showed that Retinol (Vitamin A) to the linoleoyl-arachidonoyl-glycerol ratio (β<sub>M</sub> 0.108 [95% CI 0.006, 0.210], <i>p</i> = 0.004) and the Cholesterol to linoleoyl-arachidonoyl-glycerol ratio (β<sub>M</sub> 0.238 [95% CI 0.002, 0.474], <i>p</i> = 0.048) were identified as mediators, which showed evidence of the mediated effect of the levels of Fibroblast growth factor 21 on Keloid through these mediators.</p><p><strong>Conclusion: </strong>The study presented credible evidence of a causal association between CIPs and skin fibrosis, with BMs potentially acting as a mediator in this association. These findings offer new insights into early screening and prevention of skin fibrosis.</p>","PeriodicalId":12447,"journal":{"name":"Frontiers in Endocrinology","volume":"16 ","pages":"1416993"},"PeriodicalIF":3.9,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11958232/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Frontiers in EndocrinologyPub Date : 2025-03-18eCollection Date: 2025-01-01DOI: 10.3389/fendo.2025.1529703
Caihong Li, Dongkai Cheng, Haiqin Ren, Tao Zhang
{"title":"Unraveling the gut microbiota's role in PCOS: a new frontier in metabolic health.","authors":"Caihong Li, Dongkai Cheng, Haiqin Ren, Tao Zhang","doi":"10.3389/fendo.2025.1529703","DOIUrl":"10.3389/fendo.2025.1529703","url":null,"abstract":"<p><p>Polycystic ovary syndrome (PCOS) is a common endocrine and metabolic disorder affecting reproductive-age women, characterized primarily by hyperandrogenism, ovulatory dysfunction, and metabolic abnormalities. In recent years, the gut microbiota has garnered widespread attention for its potential role as a key regulator of host metabolism in the pathogenesis of PCOS. Studies have shown that PCOS patients exhibit dysbiosis in their gut microbiota, characterized by reduced microbial diversity, an imbalance in the ratio of Firmicutes to Bacteroidetes, changes in the abundance of specific taxa, and abnormal levels of metabolic products. These alterations may exacerbate metabolic dysfunction in PCOS through multiple mechanisms, including influencing host energy metabolism, disrupting lipid and bile acid metabolism, and inducing chronic inflammation. Addressing gut dysbiosis through the modulation of patients' microbiomes-such the use of, prebiotics, fecal microbiota transplantation, and optimizing diet lifestyle-may offer strategies for improving metabolic abnormalities and alleviating clinical symptoms in PCOS. Additionally, the gut microbiome promises as a potential marker, aiding in the precise diagnosis and personalization of PCOS. Although our current understanding of how the gut microbiota influences PCOS is still limited, research is needed to explore the causal relationships and mechanisms involved, providing a more reliable theoretical basis for clinical. This review aims summarize the research progress on the relationship between gut microbiota and PCOS, and to suggest future directions to promote the development of prevention and treatment strategies for PCOS.</p>","PeriodicalId":12447,"journal":{"name":"Frontiers in Endocrinology","volume":"16 ","pages":"1529703"},"PeriodicalIF":3.9,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11958223/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Frontiers in EndocrinologyPub Date : 2025-03-18eCollection Date: 2025-01-01DOI: 10.3389/fendo.2025.1558622
Dan Zhao, Yawen Bo, Huiling Bai, Cuiping Zhao, Xinhua Ye
{"title":"Association between the minimal model of hip structure and risk of hip fracture in Chinese adults.","authors":"Dan Zhao, Yawen Bo, Huiling Bai, Cuiping Zhao, Xinhua Ye","doi":"10.3389/fendo.2025.1558622","DOIUrl":"10.3389/fendo.2025.1558622","url":null,"abstract":"<p><strong>Background: </strong>Multiple studies have indicated that the minimal model of hip structure can enhance hip fracture risk assessment. This study aimed to investigate the independent association between minimal model variables and hip fracture risk in Han Chinese individuals.</p><p><strong>Methods: </strong>This cross-sectional study included 937 Han Chinese patients (248 with hip fractures). Minimal model variables were calculated from the hip structural analysis, including bone mineral density (BMD), femoral neck width (FNW), and Delta and Sigma values.</p><p><strong>Results: </strong>This study included 937 patients (293 men; mean age = 68.3 years). In logistic regression analyses, BMD increase (per 0.1 g/cm<sup>2</sup>) correlated with a 45% reduction in the hip fracture risk (odds ratio [OR] = 0.55; 95% confidence interval [CI]: 0.45-0.68) after adjusting for all covariates. However, FNW (per 0.1 cm) and Sigma (per 0.01 cm) and Delta values (per 0.01 cm) were associated with increased risks (OR = 1.28; 95% CI: 1.18-1.37; OR = 1.06; 95% CI: 1.03-1.09; OR = 1.06; 95% CI: 1.03-1.09, respectively). When the Delta was >0.17 cm, the risk of hip fracture rose considerably by 13% (OR = 1.13; 95% CI: 1.08-1.18) for every 0.01 cm that the Delta value increased. The area under the curve (AUC) for hip fracture prediction from BMD alone was significantl lower than those of minimal model (0.781 vs 0.838, p <0.05).</p><p><strong>Conclusion: </strong>Large increases in FNW, Sigma and Delta values and notable declines in BMD were individually and significantly linked to a high hip fracture risk in Han Chinese adults. Our findings suggest that the minimal model of hip structure may improve hip fracture risk assessments.</p>","PeriodicalId":12447,"journal":{"name":"Frontiers in Endocrinology","volume":"16 ","pages":"1558622"},"PeriodicalIF":3.9,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11958231/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Frontiers in EndocrinologyPub Date : 2025-03-18eCollection Date: 2025-01-01DOI: 10.3389/fendo.2025.1503711
Qian Ming Tu, Hui Min Jin, Xiu Hong Yang
{"title":"Lipid abnormality in diabetic kidney disease and potential treatment advancements.","authors":"Qian Ming Tu, Hui Min Jin, Xiu Hong Yang","doi":"10.3389/fendo.2025.1503711","DOIUrl":"10.3389/fendo.2025.1503711","url":null,"abstract":"<p><p>Numerous studies have shown that dyslipidemia increases the risk of atherosclerotic cardiovascular disease (ASCVD) and significantly impacts the occurrence and progression of diabetic kidney disease (DKD). Early interventions for lipid metabolism disorders in DKD may improve renal function. This article reviews the clinical characteristics of dyslipidemia, mechanisms of lipid-induced renal injury, and advances in lipid-lowering therapy in DKD. We searched PubMed, Web of Science, and EMBASE to identify relevant articles, using keywords such as \"diabetic kidney disease\", \"diabetic nephropathy\", \"diabetes\", \"dyslipidemia\", \"kidney\", \"cardiovascular disease\", and \"lipid therapy\". High triglyceride (TG) and low high-density lipoprotein (HDL) are associated with increased risks of albuminuria and estimated glomerular filtration rate (eGFR) decline. Abnormal lipid metabolism may damage glomerular podocytes and renal tubular epithelial cells via ectopic lipid deposition, eventually impairing glomerular filtration function and increasing urinary albumin excretion. Lipid-lowering therapies can ameliorate lipid accumulation, downregulate inflammatory mediator expressions, and alleviate renal fibrosis. Fibrate and statin applications exhibit beneficial effects, reducing albuminuria and slowing eGFR decline in early DKD. However, the long-term effects of statins and fibrates on renal outcomes remain controversial. Pro-protein convertase subtilisin/kexin 9 (PCSK9)-targeted interventions have minimal side effects on the kidneys and seem effective in reducing inflammation and improving renal impairment compared with statins and fibrates. In addition, LDL apheresis (LDL-A) and double filtration plasmapheresis (DFPP) are promising clinical applications in diabetic patients with severe hypercholesterolemia or lipid-lowering drug intolerance.</p>","PeriodicalId":12447,"journal":{"name":"Frontiers in Endocrinology","volume":"16 ","pages":"1503711"},"PeriodicalIF":3.9,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11958226/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Frontiers in EndocrinologyPub Date : 2025-03-18eCollection Date: 2025-01-01DOI: 10.3389/fendo.2025.1554617
Laura Orioli, Jean-Paul Thissen
{"title":"Myokines as potential mediators of changes in glucose homeostasis and muscle mass after bariatric surgery.","authors":"Laura Orioli, Jean-Paul Thissen","doi":"10.3389/fendo.2025.1554617","DOIUrl":"10.3389/fendo.2025.1554617","url":null,"abstract":"<p><p>Myokines are bioactive peptides released by skeletal muscle. Myokines exert auto-, para-, or endocrine effects, enabling them to regulate many aspects of metabolism in various tissues. However, the contribution of myokines to the dramatic changes in glucose homeostasis and muscle mass induced by bariatric surgery has not been established. Our review highlights that myokines such as brain-derived neurotrophic factor (BDNF), meteorin-like protein (Metrnl), secreted protein acidic and rich in cysteine (SPARC), apelin (APLN) and myostatin (MSTN) may mediate changes in glucose homeostasis and muscle mass after bariatric surgery. Our review also identifies myonectin as an interesting candidate for future studies, as this myokine may regulate lipid metabolism and muscle mass after bariatric surgery. These myokines may provide novel therapeutic targets and biomarkers for obesity, type 2 diabetes and sarcopenia.</p>","PeriodicalId":12447,"journal":{"name":"Frontiers in Endocrinology","volume":"16 ","pages":"1554617"},"PeriodicalIF":3.9,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11958187/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Frontiers in EndocrinologyPub Date : 2025-03-18eCollection Date: 2025-01-01DOI: 10.3389/fendo.2025.1586022
Maria Margherita Rando, Federico Biscetti, Andrea Flex
{"title":"Editorial: Diagnosis, prevention and treatment in diabetic nephropathy, volume III.","authors":"Maria Margherita Rando, Federico Biscetti, Andrea Flex","doi":"10.3389/fendo.2025.1586022","DOIUrl":"https://doi.org/10.3389/fendo.2025.1586022","url":null,"abstract":"","PeriodicalId":12447,"journal":{"name":"Frontiers in Endocrinology","volume":"16 ","pages":"1586022"},"PeriodicalIF":3.9,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11958156/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Frontiers in EndocrinologyPub Date : 2025-03-18eCollection Date: 2025-01-01DOI: 10.3389/fendo.2025.1478139
Qiao Tang, Yanwei Ji, Zhongyuan Xia, Yuxi Zhang, Chong Dong, Qian Sun, Shaoqing Lei
{"title":"Identification and validation of endoplasmic reticulum stress-related diagnostic biomarkers for type 1 diabetic cardiomyopathy based on bioinformatics and machine learning.","authors":"Qiao Tang, Yanwei Ji, Zhongyuan Xia, Yuxi Zhang, Chong Dong, Qian Sun, Shaoqing Lei","doi":"10.3389/fendo.2025.1478139","DOIUrl":"10.3389/fendo.2025.1478139","url":null,"abstract":"<p><strong>Background: </strong>Diabetic cardiomyopathy (DC) is a serious complication in patients with type 1 diabetes mellitus and has become a growing public health problem worldwide. There is evidence that endoplasmic reticulum stress (ERS) is involved in the pathogenesis of DC, and related diagnostic markers have not been well-studied. Therefore, this study aimed to screen ERS-related genes (ERGs) with potential diagnostic value in DC.</p><p><strong>Methods: </strong>Gene expression data on DC were downloaded from the GEO database, and ERGs were obtained from The Gene Ontology knowledgebase. Limma package analyzed differentially expressed genes (DEGs) in the DC and control groups, and then integrated with ERGs to identify ERS-related DEGs (ERDEGs). The ERDEGs diagnostic model was developed based on a combination of LASSO and Random Forest approaches, and the diagnostic performance was evaluated by the area under the receiver operating characteristic curve (ROC-AUC) and validated against external datasets. In addition, the association of the signature genes with immune infiltration was analyzed using the CIBERSORT algorithm and the Spearman correlation test.</p><p><strong>Results: </strong>Gene expression data on DC were downloaded from the GEO database and ERGs were obtained from the Gene Ontology Knowledgebase. Limma package analysis identified 3100 DEGs between DC and control groups and then integrated with ERGs to identify 65 ERDEGs. Four diagnostic markers, Npm1, Jkamp, Get4, and Lpcat3, were obtained based on the combination of LASSO and random forest approach, and their ROC-AUCs were 0.9112, 0.9349, 0.8994, and 0.8639, respectively, which proved their diagnostic potential in DC. Meanwhile, Npm1, Jkamp, Get4, and Lpcat3 were validated by external datasets and a mouse model of type 1 DC. In addition, Npm1 was significantly negatively correlated with plasma cells, activated natural killer cells, or quiescent mast cells, whereas Get4 was significantly positively correlated with quiescent natural killer cells and significantly negatively correlated with activated natural killer cells (<i>P</i> < 0.05).</p><p><strong>Conclusions: </strong>This study provides novel diagnostic biomarkers (Npm1, Jkamp, Get4, and Lpcat3) for DC from the perspective of ERS, which provides new insights into the development of new targets for individualized treatment of type 1 diabetic cardiomyopathy.</p>","PeriodicalId":12447,"journal":{"name":"Frontiers in Endocrinology","volume":"16 ","pages":"1478139"},"PeriodicalIF":3.9,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11959167/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Oncocytic pituicytoma in a patient with Cushing's disease: a case report and narrative literature review.","authors":"Jing Li, Shuaiming Chen, Huiwen Tan, Yerong Yu, Ying Tang, Bowen Cai, Jianwei Li","doi":"10.3389/fendo.2025.1487120","DOIUrl":"10.3389/fendo.2025.1487120","url":null,"abstract":"<p><strong>Background: </strong>Posterior pituitary tumors (PPTs) are extremely rare, with fewer than 400 cases reported to date. In 2022, the World Health Organization (WHO) classified four types of tumors originating from the posterior pituitary: traditional pituicytoma, oncocytic pituicytoma, granular pituicytoma, and ependymal pituicytoma. To our knowledge, only one subject with coexistence of Cushing's disease and oncocytic pituicytoma (spindle cell oncocytoma) has been reported, but the clinical features of this patient were not described in detail.</p><p><strong>Case presentation: </strong>We presented a case of a patient with Cushing's syndrome and a pituitary mass. Transsphenoidal surgery was performed, and pathologic examination revealed two distinct tumors: a corticotroph adenoma with a diameter of less than 2 mm and a larger oncocytic pituicytoma. Post-surgery serum cortisol was 51 nmol/L, indicating complete remission. Corticotroph adenoma or corticotroph hyperplasia was identified after surgery in less than half of the subjects with Cushing's disease and PPT.</p><p><strong>Conclusions: </strong>Our study indicates that Cushing's disease in patients with PPT may be caused by the existence of collision lesions, with corticotroph adenoma or hyperplasia being difficult to detect due to their small dimensions.</p>","PeriodicalId":12447,"journal":{"name":"Frontiers in Endocrinology","volume":"16 ","pages":"1487120"},"PeriodicalIF":3.9,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11958162/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Frontiers in EndocrinologyPub Date : 2025-03-18eCollection Date: 2025-01-01DOI: 10.3389/fendo.2025.1560981
Hong Yi, Lin Chen, Jinglei Zhang, Yangxing Wen, Xi Zheng, Xiaoyan Chen
{"title":"Infertility management in resistant ovary syndrome: a review.","authors":"Hong Yi, Lin Chen, Jinglei Zhang, Yangxing Wen, Xi Zheng, Xiaoyan Chen","doi":"10.3389/fendo.2025.1560981","DOIUrl":"10.3389/fendo.2025.1560981","url":null,"abstract":"<p><p>Resistant ovary syndrome is a rare endocrinological disorder characterized by elevated serum gonadotropins and normal ovarian reserves. The leading causes of this condition include <i>FSHR</i> mutations, and autoimmune disorders. Due to follicle maturation defects and anovulation, these patients have menstrual disturbances and infertility. Endocrinological disorders can be treated by regular hormone replacement therapy. However, there is no consensus regarding the infertility issues and current treatment remains experimental with controlled ovarian stimulation (COS) and <i>in vitro</i> maturation. Herein, we conducted a review of the current literature, which concludes that: 1) patients with <i>FSHR</i> mutations had very poor COS outcomes; 2) follicle-stimulating hormone and luteinizing hormone levels poorly predict COS outcomes; 3) both recombinant and urinary gonadotropins may be effective in COS; 4) the dosage of exogenous gonadotropins is not the key to successful COS; 5) <i>in vitro</i> maturation is a feasible option for patients carrying <i>FSHR</i> mutations or unsuccessful COS cycles.</p>","PeriodicalId":12447,"journal":{"name":"Frontiers in Endocrinology","volume":"16 ","pages":"1560981"},"PeriodicalIF":3.9,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11958170/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}